User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Primary tabs

Giles, F.J. Abruzzese, E. Rosti, G. Kim, D.-W. Bhatia, R. Bosly, André [UCL] Kantarjian, H.M.

Nilotinib is a highly selective Bcr-Abl inhibitor approved for imatinib-resistant chronic myeloid leukemia (CML). Nilotinib and dasatinib, a multi-targeted kinase inhibitor also approved for second-line therapy in CML, have different patterns of kinase selectivity, pharmacokinetics, and cell uptake and efflux properties, and thus patients may respond to one following failure of the other. An international phase II study of nilotinib was conducted in CML patients (39 chronic phase (CP), 21 accelerated phase (AP)) after failure of both imatinib and dasatinib. Median times from diagnosis of CP or AP to nilotinib therapy were 89 and 83 months, respectively. Complete hematological response and major cytogenetic response (MCyR) rates in CP were 79% and 43%, respectively. Of 17 evaluable patients with CML-AP, 5 (29%) had a confirmed hematological response and 2 (12%) a MCyR. The median time to progression has not yet been reached in CP patients. At 18 months 59% of patients were progression-free. Median overall survival for both populations has not been reached, and the estimated 18-month survival rate in CML-CP was 86% and that at 12 months for CML-AP was 80%. Nilotinib is an effective therapy in CML-CP and-AP following failure of both imatinib and dasatinib therapy. © 2010 Macmillan Publishers Limited All rights reserved.

Document type Article de périodique (Journal article)
Publication date 2010
Language Anglais
Journal information "Leukemia" - Vol. 24, no.7, p. 1299-1301 (2010)
Peer reviewed yes
Publisher Nature Publishing Group ((United Kingdom) London)
issn 0887-6924
e-issn 1476-5551
Publication status Publié
Affiliations UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - (MGD) Service d'hématologie
Keywords Abl inhibitors ; Dasatinib ; Imatinib ; Nilotinib ; Resistance
Links
  1. Giles F J, O'Dwyer M, Swords R, Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia, 10.1038/leu.2009.111
  2. O'Hare T., Eide C. A., Deininger M. W. N., Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia, 10.1182/blood-2007-03-066936
  3. Baccarani Michele, Cortes Jorge, Pane Fabrizio, Niederwieser Dietger, Saglio Giuseppe, Apperley Jane, Cervantes Francisco, Deininger Michael, Gratwohl Alois, Guilhot François, Hochhaus Andreas, Horowitz Mary, Hughes Timothy, Kantarjian Hagop, Larson Richard, Radich Jerald, Simonsson Bengt, Silver Richard T., Goldman John, Hehlmann Rudiger, Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet, 10.1200/jco.2009.25.0779
  4. Hochhaus A, O'Brien S G, Guilhot F, Druker B J, Branford S, Foroni L, Goldman J M, Müller M C, Radich J P, Rudoltz M, Mone M, Gathmann I, Hughes T P, Larson R A, Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, 10.1038/leu.2009.38
  5. Quintas-Cardama A., Kantarjian H., Jones D., Nicaise C., O'Brien S., Giles F., Talpaz M., Cortes J., Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure, 10.1182/blood-2006-07-035493
  6. Goldman John M., Chronic Myeloid Leukemia: Reversing the Chronic Phase, 10.1200/jco.2009.26.5587
  7. Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian H M, Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history, 10.1038/leu.2009.193
  8. Hiwase D. K., Saunders V., Hewett D., Frede A., Zrim S., Dang P., Eadie L., To L. B., Melo J., Kumar S., Hughes T. P., White D. L., Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications, 10.1158/1078-0432.ccr-07-5095
  9. Eadie L, Hughes T P, White D L, Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells, 10.1038/leu.2010.7
  10. Hiwase D K, White D, Zrim S, Saunders V, Melo J V, Hughes T P, Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy, 10.1038/leu.2009.242
Bibliographic reference Giles, F.J. ; Abruzzese, E. ; Rosti, G. ; Kim, D.-W. ; Bhatia, R. ; et. al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. In: Leukemia, Vol. 24, no.7, p. 1299-1301 (2010)
Permanent URL http://hdl.handle.net/2078.1/124232